Robert Olstein
Olstein Capital Management
Robert Olstein Haemonetics Corp stake
total: 342
Olstein Capital Management HAE trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2014 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2014 Q2
According to 2026 Q2 report, Robert Olstein doesn't hold any Haemonetics Corp (HAE) shares. To date, the estimated cost basis is nearly $32.57 for "buy" trades and estimated average "sell" price is $32.57. Olstein Capital Management first purchased HAE in 2014 Q1, initially acquiring 14,400 shares. Since the initial investment in Haemonetics Corp (HAE), Olstein Capital Management has made 1 more transaction.
When did Robert Olstein sell Haemonetics Corp (HAE)?
Robert Olstein sold off the entire Haemonetics Corp (HAE) position in 2014 Q2.
When did Robert Olstein buy Haemonetics Corp (HAE)?
Robert Olstein first invested in Haemonetics Corp (HAE) in 2014 Q1 at the reported quarter-end price of $32.57 per share.
What's the cost basis of Olstein Capital Management's HAE stake?
The estimated cost basis for Haemonetics Corp (HAE) stake is around $32.57 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $32.57
- Weighted AVG sell price:
- $32.57
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.